LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Ovid therapeutics Inc

Gesloten

SectorGezondheidszorg

1.22 -0.81

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.16

Max

1.24

Belangrijke statistieken

By Trading Economics

Inkomsten

5.6M

-4.7M

Verkoop

6.1M

6.3M

Winstmarge

-74.681

Werknemers

23

EBITDA

7.3M

-5.1M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+176.42% upside

Dividenden

By Dow Jones

Volgende Winsten

10 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

52M

91M

Vorige openingsprijs

2.03

Vorige sluitingsprijs

1.22

Nieuwssentiment

By Acuity

50%

50%

173 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Ovid therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 sep 2025, 23:59 UTC

Acquisities, Fusies, Overnames

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 sep 2025, 22:02 UTC

Belangrijke Marktbewegers

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 sep 2025, 17:01 UTC

Belangrijke Marktbewegers

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 sep 2025, 17:01 UTC

Belangrijke Marktbewegers

Tron Shares Rise After New Investment From Bravemorning

8 sep 2025, 16:14 UTC

Belangrijke Marktbewegers

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 sep 2025, 16:13 UTC

Belangrijke Marktbewegers

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 sep 2025, 23:12 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 sep 2025, 23:12 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 sep 2025, 23:12 UTC

Marktinformatie

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 sep 2025, 22:56 UTC

Marktinformatie

Worst May Be Over for New Zealand Retailers -- Market Talk

8 sep 2025, 22:23 UTC

Marktinformatie

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 sep 2025, 21:51 UTC

Marktinformatie

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 sep 2025, 21:47 UTC

Belangrijke Marktbewegers

Microsoft Signs $17.4B AI Deal With Nebius

8 sep 2025, 21:33 UTC

Acquisities, Fusies, Overnames

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 sep 2025, 21:20 UTC

Acquisities, Fusies, Overnames

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 sep 2025, 21:19 UTC

Acquisities, Fusies, Overnames

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 sep 2025, 21:18 UTC

Acquisities, Fusies, Overnames

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 sep 2025, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

8 sep 2025, 19:33 UTC

Marktinformatie

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 sep 2025, 19:22 UTC

Marktinformatie

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 sep 2025, 19:02 UTC

Marktinformatie

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 sep 2025, 18:24 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 sep 2025, 18:24 UTC

Marktinformatie

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 sep 2025, 17:29 UTC

Marktinformatie

Mexican Inflation Seen Little Changed in August -- Market Talk

8 sep 2025, 16:59 UTC

Marktinformatie
Acquisities, Fusies, Overnames

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 sep 2025, 16:36 UTC

Marktinformatie

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 sep 2025, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

8 sep 2025, 16:16 UTC

Winsten

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 sep 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 sep 2025, 16:04 UTC

Marktinformatie

Global Equities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Ovid therapeutics Inc Prognose

Koersdoel

By TipRanks

176.42% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3.4 USD  176.42%

Hoogste 5.5 USD

Laagste 1.5 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ovid therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technische score

By Trading Central

0.275 / 0.33Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

173 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat